NCT01660906 2016-11-22Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibBristol-Myers SquibbPhase 4 Completed39 enrolled 14 charts